DK1107940T3 - Vitamin D3-mimiske forbindelser - Google Patents

Vitamin D3-mimiske forbindelser

Info

Publication number
DK1107940T3
DK1107940T3 DK99941140T DK99941140T DK1107940T3 DK 1107940 T3 DK1107940 T3 DK 1107940T3 DK 99941140 T DK99941140 T DK 99941140T DK 99941140 T DK99941140 T DK 99941140T DK 1107940 T3 DK1107940 T3 DK 1107940T3
Authority
DK
Denmark
Prior art keywords
vitamin
compounds
present
mimic compounds
show
Prior art date
Application number
DK99941140T
Other languages
English (en)
Inventor
Elizabeth A Allegretto
Marcus F Boehm
Alex M Nadzan
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Application granted granted Critical
Publication of DK1107940T3 publication Critical patent/DK1107940T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/20—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms using aldehydes or ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99941140T 1998-08-24 1999-08-12 Vitamin D3-mimiske forbindelser DK1107940T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/139,040 US6218430B1 (en) 1998-08-24 1998-08-24 Vitamin D3 mimics
PCT/US1999/018502 WO2000010958A1 (en) 1998-08-24 1999-08-12 Vitamin d3 mimics

Publications (1)

Publication Number Publication Date
DK1107940T3 true DK1107940T3 (da) 2004-03-08

Family

ID=22484839

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99941140T DK1107940T3 (da) 1998-08-24 1999-08-12 Vitamin D3-mimiske forbindelser

Country Status (11)

Country Link
US (1) US6218430B1 (da)
EP (1) EP1107940B1 (da)
JP (1) JP2002523388A (da)
AT (1) ATE253032T1 (da)
AU (1) AU756336B2 (da)
CA (1) CA2339775A1 (da)
DE (1) DE69912450T2 (da)
DK (1) DK1107940T3 (da)
ES (1) ES2207273T3 (da)
PT (1) PT1107940E (da)
WO (1) WO2000010958A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
CA2326117A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
AU4676999A (en) * 1998-06-12 1999-12-30 Ligand Pharmaceuticals, Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
DE60328286D1 (de) 2002-05-29 2009-08-20 Lilly Co Eli Vitamin-d-rezeptormodulatoren vom phenyl-thiophen-typ
ES2275106T3 (es) * 2002-08-27 2007-06-01 GALDERMA RESEARCH & DEVELOPMENT, S.N.C. Analogos de la vitamina d.
AU2003287500B2 (en) * 2002-11-22 2009-11-19 Eli Lilly And Company Vitamin D receptor modulators
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060094778A1 (en) * 2003-01-10 2006-05-04 Eli Lilly And Company, An Indiana Corporation Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7863298B2 (en) * 2003-10-14 2011-01-04 Exelixis, Inc. Bridged ring structures as pharmaceutical agents
US7750184B2 (en) * 2003-11-20 2010-07-06 Eli Lilly And Company Vitamin D receptor modulators
ATE370941T1 (de) * 2003-11-20 2007-09-15 Lilly Co Eli Modulatoren des vitamin-d-rezeptors
US7595345B2 (en) 2003-11-20 2009-09-29 Eli Lilly And Company Vitamin D receptor modulators
CA2544857A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
WO2005051936A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Phenyl-furan compounds as vitamin d receptor modulators
TW200600494A (en) * 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
KR20070028400A (ko) * 2004-05-04 2007-03-12 아카디아 파마슈티칼스 인코포레이티드 에스트로겐 리셉터에 활성을 갖는 화합물
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
PL1836151T3 (pl) * 2004-12-21 2009-08-31 Lilly Co Eli Modulatory receptora witaminy D
TW200716536A (en) 2005-06-09 2007-05-01 Chugai Pharmaceutical Co Ltd Vitamin D compounds
US8674007B2 (en) 2006-07-12 2014-03-18 Sabic Innovative Plastics Ip B.V. Flame retardant and scratch resistant thermoplastic polycarbonate compositions
EP1947463A1 (en) * 2007-01-16 2008-07-23 Roche Diagnostics GmbH Collection of liquid analytical samples for clinical analytical purpose
CN105012282A (zh) * 2008-07-02 2015-11-04 不列颠哥伦比亚癌症局分支机构 二缩水甘油醚衍生物治疗剂和它们的使用方法
EP2393494A1 (en) * 2009-01-27 2011-12-14 Berg Biosystems, LLC Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
JP2010208997A (ja) * 2009-03-11 2010-09-24 Okayama Univ 置換ジフェニルメタン酸誘導体を含有する医薬組成物
CA2770683C (en) 2009-08-14 2018-09-04 Berg Biosystems, Llc Vitamin d3 and analogs thereof for treating alopecia
WO2011082487A1 (en) 2010-01-06 2011-07-14 British Columbia Cancer Agency Branch Bisphenol derivatives and their use as androgen receptor activity modulators
EP2693875A4 (en) * 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHODS OF USE
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
US9173939B2 (en) 2013-05-10 2015-11-03 The University Of British Columbia Ester derivatives of androgen receptor modulators and methods for their use
SG10201709894RA (en) 2013-05-29 2018-01-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
WO2015031984A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
DK3245193T3 (da) 2015-01-13 2022-03-07 British Columbia Cancer Agency Branch Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
AU2019362061A1 (en) 2018-10-18 2021-05-06 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CA3174422A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH145895A (de) 1928-04-07 1931-03-15 Ig Farbenindustrie Ag Verfahren zur Darstellung von 4-Methyl-5.7-dichlor-(2)-thionaphten-4'-chlor-7'-methoxy-(2')-indolindigo.
BE613143A (fr) * 1961-01-27 1962-07-26 Ciba Geigy Nouveaux phénoxy-éthers et procédé pour leur préparation
US3298998A (en) 1961-03-07 1967-01-17 Eastman Kodak Co Bisglycidyl ethers of bisphenols
US3410825A (en) 1967-02-27 1968-11-12 Eastman Kodak Co Bis[p-(2, 3-epoxypropoxy)phenyl]polycyclic saturated hydrocarbons and synthetic resinous polyethers thereof
JPS4931651A (da) * 1972-07-20 1974-03-22
DE2404380C3 (de) 1974-01-30 1980-09-18 Espe Fabrik Pharmazeutischer Praeparate Gmbh, 8031 Seefeld Verwendung bifunktioneller Äthyleniminverbindungen bei der Herstellung zahnärztlicher Modelle und Zahnersatzteile
US4093555A (en) 1974-01-30 1978-06-06 Espe Fabrik Pharmazeutischer Praparate Gmbh Production of dental models and tooth replacement parts
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
WO1991004957A1 (en) 1989-10-04 1991-04-18 Gaf Chemicals Corporation Alk-1-enyl ethers
US4983191A (en) * 1989-10-10 1991-01-08 E. I. Du Pont De Nemours And Company Production of aromatic polyimide membranes
US5128491A (en) 1991-07-30 1992-07-07 Ciba-Geigy Corporation Process for the preparation of glycidyl ethers of di-secondary alcohols with high monomer content

Also Published As

Publication number Publication date
AU756336B2 (en) 2003-01-09
CA2339775A1 (en) 2000-03-02
JP2002523388A (ja) 2002-07-30
DE69912450D1 (de) 2003-12-04
ES2207273T3 (es) 2004-05-16
EP1107940B1 (en) 2003-10-29
ATE253032T1 (de) 2003-11-15
DE69912450T2 (de) 2004-07-29
WO2000010958A9 (en) 2000-07-13
US6218430B1 (en) 2001-04-17
EP1107940A1 (en) 2001-06-20
PT1107940E (pt) 2004-03-31
WO2000010958A1 (en) 2000-03-02
AU5485299A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
DK1107940T3 (da) Vitamin D3-mimiske forbindelser
TR200001546T2 (tr) Serin/treonin protein kinaz fonksiyonunu modüle etmek için azabenzimidazol esaslı bileşikler.
YU67694A (sh) Ne-peptidni antagosnisti receptora tahikinina
DE69213231D1 (de) Zusammensetzung und methode zur verstärkung der sonnenbräunung
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE127691T1 (de) Verwendung von vitamin-d-analoga zur behandlung von akne.
CA2202879A1 (en) Calcium receptor-active compounds
DE69204663D1 (de) Verarbeitungsöl für gummi und dieses enthaltende gummiprodukte.
AU8101698A (en) Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
IS4404A (is) Afleiður steróla til stýringar rýrisskiptingu
AU1876788A (en) Methylene phosphonoalkylphosphinates, pharmaceutical compositions , and methods for treating abnormal calcium and phosphate metabolism
MX9101451A (es) Sistema de silicona de un componente,vulcanizables bajo la accion de la humedad
MXPA02012553A (es) Miembro electrofotografico fotosensible, cartucho de proceso y aparato electrofotografico.
WO2002079474A3 (en) Human b7 polypeptides
EP1348768A3 (en) Method of treatment, diagnosis or detection of diabetes
BR0009527A (pt) Sistema e método de pré-qualificação e de concessão de crédito
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
ATE305517T1 (de) Neurotrypsin
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
TR199800941T2 (xx) Siklik polisiloksanlara dayal� ha�ere kontrol bile�imleri.
NO20004708L (no) Anvendelse av naturlig og/eller syntetisk kininsyre og/eller forlöpere derav som anti-insektsmiddel
AU7390891A (en) Anti-oncostatin m monoclonal antibodies
WO1998029566A3 (en) Novel method for testing the differentiation status in pancreatic cells of a mammal
PT865284E (pt) Composicoes contendo bismuto e um ou mais anti-microbioticos para a prevencao e tratamento de perturbacoes gastrointestinais
Laughlin Draft guidance issued for source protection